Interestingly, the prognostic value of copeptin for re-events was significantly higher among patients with stroke or TIA of cardioembolic source, as elevated plasma copeptin levels within this group were accompanied by a 4-fold increased risk of subsequent vascular events during 1-year follow-up. The gene discussed is AVP; the disease is stroke disorder.